Publications by authors named "V van der Noort"
Motivation: Much of prokaryotic comparative genomics currently relies on two critical computational tasks: pangenome inference and core genome inference. Pangenome inference involves clustering genes from a set of genomes into gene families, enabling genome-wide association studies and evolutionary history analysis. The core genome represents gene families present in nearly all genomes and is required to infer a high-quality phylogeny.
View Article and Find Full Text PDFArticle Synopsis
- CDK4/6 inhibitors combined with endocrine therapy improve outcomes for patients with hormone-receptor positive, HER2-negative advanced breast cancer, but evidence comparing first-line and second-line use is limited.
- The phase 3 SONIA trial involved 1,050 patients and showed no significant overall benefit for using CDK4/6 inhibitors first-line compared to second-line (31.0 vs. 26.8 months median progression-free survival).
- Although first-line treatment led to longer duration of CDK4/6 therapy and more severe side effects, the quality of life was similar for both treatment timing, questioning the necessity for first-line CDK4/6 inhibitor usage in all cases.
Article Synopsis
- - The study investigates mechanisms of resistance in patients with EGFR mutated non-small cell lung cancer (NSCLC) who progressed on osimertinib treatment, using paired plasma and tumor samples for analysis.
- - Out of 51 patients, the driver mutation was found in 82% of plasma samples and 98% of tumor samples, with a concordance rate of 80%, while resistance mechanisms (RMs) were identified in 80% of patients.
- - The findings suggest that analyzing both plasma and tumor samples provides a more comprehensive understanding of osimertinib resistance, with plasma identifying 61.5% and tumor analysis revealing 75% of RMs, leading to better treatment strategies.
Long-term survival following anti-PD-(L)1 monotherapy in advanced urothelial cancer and an assessment of potential prognostic clinical factors: a multicentre observational study.
BJC Rep
October 2024
Background: Anti-PD-(L)1 agent are approved as first- and second-line treatment options in advanced urothelial cancer (UC), but information about long-term survival is scarce. There is a need for prognostic factors, as these may help in the decision-making concerning anti-PD-(L)1 in patients with UC. Here, we examined long-term survival following anti-PD-(L)1 in advanced UC and assessed clinical factors for their correlation with survival.
View Article and Find Full Text PDFBacteria employ a myriad of regulatory mechanisms to adapt to the continuously changing environments that they face. They can, for example, use post-translational modifications, such as Nε-lysine acetylation, to alter enzyme activity. Although a lot of progress has been made, the extent and role of lysine acetylation in many bacterial strains remains uncharted.
View Article and Find Full Text PDF